AIM: To validate the gubra DIO-rats as a useful animal model of human obesity. METHODS: The gubra diet-induced obesity (DIO) rat model was based on male Sprague-Dawley rats with ad libitum access to regular chow and a palatable diet rich in fat and sugar. To evaluate the versatility of the gubra DIO-rats as a valid model of human obesity syndrome, the efficacy of 2 weight loss compounds liraglutide and sibutramine with different mechanisms of action were examined in 7-month-old gubra DIO-rats. Liraglutide (200 μg/kg, sc) was administered bi-daily, and sibutramine (5 mg/kg, po) was administered once daily for 23 d. RESULTS: Both the compounds effectively reduced the food intake, body weight and total fat mass as measured by nuclear magnetic resonance. Whereas the 5-HT reuptake inhibitor/5-HT receptor agonist sibutramine reduced the intake of both chow and the gubra-diet, the GLP-1 analogue liraglutide predominantly reduced the intake of the highly palatable diet, indicating a shift in food preference. Sibutramine lowered the insulin sensitivity index, primarily via reductions in glucose-stimulated insulin secretion. CONCLUSION: This animal model responds well to 2 weight loss compounds with different mechanisms of action. Moreover, the gubra DIO-rat can be particularly useful for the testing of compounds with potential effects on diet preference.
AIM: To validate the gubra DIO-rats as a useful animal model of humanobesity. METHODS: The gubra diet-induced obesity (DIO) rat model was based on male Sprague-Dawley rats with ad libitum access to regular chow and a palatable diet rich in fat and sugar. To evaluate the versatility of the gubra DIO-rats as a valid model of humanobesity syndrome, the efficacy of 2 weight loss compounds liraglutide and sibutramine with different mechanisms of action were examined in 7-month-old gubra DIO-rats. Liraglutide (200 μg/kg, sc) was administered bi-daily, and sibutramine (5 mg/kg, po) was administered once daily for 23 d. RESULTS: Both the compounds effectively reduced the food intake, body weight and total fat mass as measured by nuclear magnetic resonance. Whereas the 5-HT reuptake inhibitor/5-HT receptor agonist sibutramine reduced the intake of both chow and the gubra-diet, the GLP-1 analogue liraglutide predominantly reduced the intake of the highly palatable diet, indicating a shift in food preference. Sibutramine lowered the insulin sensitivity index, primarily via reductions in glucose-stimulated insulin secretion. CONCLUSION: This animal model responds well to 2 weight loss compounds with different mechanisms of action. Moreover, the gubra DIO-rat can be particularly useful for the testing of compounds with potential effects on diet preference.
Authors: Torsten Olbers; Sofia Björkman; Ak Lindroos; Almantas Maleckas; Lars Lönn; Lars Sjöström; Hans Lönroth Journal: Ann Surg Date: 2006-11 Impact factor: 12.969
Authors: Kristy M Heppner; Melissa Kirigiti; Anna Secher; Sarah Juel Paulsen; Rikley Buckingham; Charles Pyke; Lotte B Knudsen; Niels Vrang; Kevin L Grove Journal: Endocrinology Date: 2015-01 Impact factor: 4.736
Authors: Sanaz Gabery; Casper G Salinas; Sarah J Paulsen; Jonas Ahnfelt-Rønne; Tomas Alanentalo; Arian F Baquero; Stephen T Buckley; Erzsébet Farkas; Csaba Fekete; Klaus S Frederiksen; Hans Christian C Helms; Jacob F Jeppesen; Linu M John; Charles Pyke; Jane Nøhr; Tess T Lu; Joseph Polex-Wolf; Vincent Prevot; Kirsten Raun; Lotte Simonsen; Gao Sun; Anett Szilvásy-Szabó; Hanni Willenbrock; Anna Secher; Lotte Bjerre Knudsen; Wouter Frederik Johan Hogendorf Journal: JCI Insight Date: 2020-03-26
Authors: Louise S Dalbøge; Philip J Pedersen; Gitte Hansen; Katrine Fabricius; Henrik B Hansen; Jacob Jelsing; Niels Vrang Journal: PLoS One Date: 2015-08-12 Impact factor: 3.240